Tempus AI, the healthcare technology company that applies artificial intelligence to cancer diagnosis and treatment, has agreed to buy Personalis in a deal valued at about $1.5 billion.
The acquisition gives Tempus full control of Personalis's NeXT Personal test, which detects microscopic traces of tumour DNA in a patient's blood to catch early signs that a cancer is returning.
That capability, known as minimal residual disease monitoring, sits in a market Tempus estimates is worth $20 billion.
The deal builds on an existing relationship, since Tempus first invested in Personalis in November 2023 to help commercialise the same test.
Personalis shareholders will receive $16.25 a share, a 6% premium to Friday's close and 28% above the stock's average price over the previous 30 days.
Yet both stocks fell on the announcement, with Tempus dropping more than 8% and Personalis down 11.5%.
The reaction looks counterintuitive for a company being acquired at a premium, but the structure explains it.
The transaction is being paid in Tempus shares rather than cash, with the buyer able to fund up to half in cash if it chooses.
Crucially, the number of Tempus shares each Personalis holder receives is capped at a fixed ratio.
That ties the real value of the offer to Tempus's own share price, so when Tempus falls, the effective payout to Personalis shareholders falls with it.
With the deal not expected to close until late 2026 or early 2027, that leaves a long window in which Tempus's stock, already down 18% this year and trading below a closely watched moving average, could drift further.
The wider context is a brutal sell-off across healthcare and technology names, which has dragged Tempus lower regardless of the merits of the purchase.
For Tempus, the logic is straightforward: it is buying a technology it already knows well and folding it into its AI and data platform to monitor patients from diagnosis through to recurrence.
Personalis brings growing momentum, with quarterly revenue of $22.4 million and test volumes up 33% on the previous quarter.
The market's scepticism is less about the strategy than the price of Tempus's own paper being used to fund it.
